Daron Evans, CFO at Rezolute, Inc. (RZLT), bought 10,000 shares at $2.85 ($29K) on 2026-03-30, disclosed to the SEC on 2026-03-31.
Rezolute CFO Daron Evans purchased 10,000 shares for $28,500 on March 30, signaling confidence in the biotech's turnaround potential. This buy comes as the stock has recovered 29.24% over the last 90 days despite remaining 73.38% below its 52-week high.
The stock is currently trading at $3.05, having surged 13.38% over the past five days despite a 4.98% decline over the last 30 days. It remains significantly undervalued relative to its 52-week high of $11.46, sitting 73.38% below that level.
Catalysts include the upcoming FDA discussion on a potential path forward for ersodetug under its Breakthrough Therapy Designation, following the March 25 news update. Additionally, the company continues its Phase 3 upLIFT study in tumor hyperinsulinism, which remains a key pipeline milestone.
The stock carries significant risk with a short interest of 21.66% of the float, indicating heavy bearish positioning. Furthermore, the recent failure of the Phase 3 sunRIZE study in congenital hyperinsulinism casts doubt on the near-term commercial viability of the company's lead asset.
Clearly above the average filing.
| Filing → |
| RZLT | BUY | 2025-03-28 | $58K | — | Filing → |
| RZLT | BUY | 2024-12-18 | $43K | — | Filing → |
| RZLT | BUY | 2024-12-12 | $41K | — | Filing → |